Clinical Recommendations For Parkinson's Disease Assignment Sample

• Type Assignment
• Downloads546
• Pages5
• Words1285

A. Neurology & Diagnostic Follow-up

It is important to follow up on the patients with genetically confirmed Parkinson's disease, especially in early or atypical onset, as with the PARK2 mutation or LRRK2. Under regular surveillance, early action could be taken as the symptoms keep advancing, and it could provide individualised care to the individual in line with his/her phenotype. Clinical rating scales “(Unified Parkinson's Disease Rating Scale or Movement Disorder Society-sponsored revision)” play an important role in assessing motor and non-motor symptoms across time. Cognitive changes or psychiatric symptoms are also an indication of imaging and neuropsychological assessment (Khan et al. 2025). Collaboration with the specialists in the field of movement disorders allows precise monitoring of the progression of the disease and prompt changes in treatment, which is crucial to the quality of life and the delay in declining the chances of the functional level.

Clinical Recommendations For Parkinson's Disease Assignment Sample

Liked This Sample? Hire Me Now

Alan White 10 Years | MSc in Nursing

Struggling with tight deadlines? Assignment Help For Students from Rapid Assignment Help UK delivers well-researched, expertly written papers on time, every time.

B. Pharmacologic Treatment

The process of pharmacologic management needs to initiate with levodopa/carbidopa, which has been used as the standard in the management of motor symptoms of PD, such as tremor, rigidity, and bradykinesia. In hereditary PD, especially genetically aberrant Parkinson's with PARK2 mutations leading to early-onset PD, such individuals tend to have good initial treatment response to levodopa; however, they also have a greater tendency to early onset of motor complications such as dyskinesia. Dopamine agonists and monoamine oxidase B (MAO-B) inhibitors can be employed at the early stages or as an adjunct to decrease the dose of levodopa and delay motor transition (Khanna, & Jones, 2023).

When a patient is advanced, the treatment may include ‘catechol-O-methyl transferase inhibitors or Apo morphine’ to treat the off period. Selecting a drug based on the genotype of the patient might be important to intervene, e.g., carriers of LRRK2 mutation may also take different drugs than others, and so a pharmacogenomic approach may prove valuable. It helps to avoid excessive responses or other adverse effects, such as impulse control disorders or hallucinations, because it is important to balance its efficacy and possible adverse effects through careful titration. The education of patients on adherence to the drugs and the side effects is part of the success of the compliance with medication.

C. Multidisciplinary Support

The multidisciplinary model of care is essential to facilitate the prevention of various symptoms of PD. It must be treated using physiotherapy as early as possible, and it should include gait training, balance training, and muscle strengthening to minimize the risk of falls and achieve mobility. Occupational therapy can aid in the modification of daily living skills such as self-care, food preparation, and home mobility (Stocchi et al. 2024). Speech and language therapists assist patients living with dysphagia or hypophonia because they are prevalent in moderate and severe PD.

Nutritionists are in a position to assist in the management of unintentional weight loss and optimal nutrient intake, particularly for patients who have difficulty swallowing. There should also be an option of cognitive behavioural therapy or psychological support for those patients with problems of depression, apathy, or anxiety. It is possible that genetic PD exerts a psychological load with a family implication, and it is a reason why it is necessary to provide a holistic mental health support. Interdisciplinary cooperation thus provides coordinated care and gives patients more effective control over their complicated interactions between motor, cognitive, and emotional symptoms.

D. Genetic Counseling

An important part of inherited PD is genetic counselling. When the mutation is identified(PARK2, autosomal recessive, or LRRK2, autosomal dominant)’, patients should be provided with comprehensive counselling to gain an idea of the pattern of inheritance, the consequences to the family members, and ways of reproducing without risk of mutant inheritance. Predictive genetic testing can be offered to first-degree relatives, but this must be done with caution, especially when there is no symptom present (Tanaka, 2025). Testing on underage individuals is advisable where there is no benefit of clinical outcomes from intervening in a case.

There should be counselling sessions that involve the discussion of penetrance, variability in the age of onset, and unpredictability of the progression of the diseases. Such ethical issues as informing family members, psychological implications of genetic data, and so on, require special handling. In families that plan pregnancies, reproductive options such as preimplantation genetic diagnosis or preimplantation embryo screening by in vitro fertilisation may be advisable.

E. Lifestyle, Mental Health & Safety

The conversion of lifestyle is of prime importance in managing PD and enhancing the long-term outcomes. Interventions that focus on the prevention of falls are home safety assessment, assistive devices, and training caregivers. With the advance of PD, there is an increased risk of cognitive deterioration, psychosis, and mood disorders. It is advised to conduct routine screening with the help of scales like the ‘Montreal Cognitive Assessment or the Geriatric Depression Scale’. Depression or anxiety can be treated with cognitive behavioural therapy and a selective serotonin reuptake inhibitor (Amin, & Elberry, 2025).

It is possible to maintain daily functioning by taking care of the schedule of medicines, simplifying tasks, and adapting the environment. The development of the disease can be prevented by encouraging frequent exercise, social interaction, and stimulating the mind. Emotional or psychological support, fighting loneliness, and empowering the patient to deal with their options are some of the things that support groups can accomplish.

F. Long-Term Care Planning

Advance planning is important, and the discussion should start in advance, concerning the expected disease progression and future care needs. When motor and cognitive symptoms become medium and severe, patients might be in need of help with simple activities, which will either mean using home care services or transferring to assisted living facilities. It is important to draw up an advance desire plan and nominate a power of attorney so that the desire of the patient is taken into account in subsequent stages (Tian et al. 2025).

Caregivers need support in order to avoid burnout and ensure continuity of care. It entails respite, counselling, and learning materials. The families can be more prepared through the early preparation process to handle the changing needs in the care process, and there will be fewer elements of emotional pain when the disease progresses.

Conclusion

The treatment of the genetic type of Parkinson's is a multidisciplinary therapy that includes a personalised approach consisting of pharmacologic therapy, rehabilitation, and psychosocial support. The Clinical guidelines need to be personalized according to the genotype, symptom severity, and lifestyle. It is important to plan the long-term follow-up with a neurologist, genetic guidance, and counselling. By use of proper interventions, the patients may live with a quality of life and functioning in various stages of the disease.

Reference List

Journals

• Amin, S. N., & Elberry, D. A. (2025). The Role of Neurotransmitters in the Pathophysiology of Parkinson's Disease. In Zebrafish as a Model for Parkinson’s Disease (pp. 139-153). CRC Press. [Retrieved from: https://www.taylorfrancis.com/chapters/edit/10.1201/9781003402893-14/role-neurotransmitters-pathophysiology-parkinson-disease-shaimaa-nasr-amin-dalia-azmy-elberry] Retrieved on: 2.07.2025
• Khan, M. S., Nasiripour, S., & Bopassa, J. C. (2025). Parkinson Disease Signaling Pathways, Molecular Mechanisms, and Potential Therapeutic Strategies: A Comprehensive Review. International Journal of Molecular Sciences, 26(13), 6416. [Retrieved from: https://www.mdpi.com/1422-0067/26/13/6416] Retrieved on: 2.07.2025
• Khanna, A., & Jones, G. (2023). Toward personalized medicine approaches for Parkinson disease using digital technologies. JMIR Formative Research, 7(1), e47486. [Retrieved from: https://formative.jmir.org/2023/1/e47486/] Retrieved on: 2.07.2025
• Stocchi, F., Bravi, D., Emmi, A., & Antonini, A. (2024). Parkinson disease therapy: current strategies and future research priorities. Nature Reviews Neurology, 20(12), 695-707. [Retrieved from:https://www.researchgate.net/profile/Aron-Emmi/publication/385522490_Parkinson_disease_therapy_current_strategies_and_future_research_priorities/links/6731cf045852dd723cb65b6c/Parkinson-disease-therapy-current-strategies-and-future-research-priorities.pdf] Retrieved on: 2.07.2025
• Tanaka, M. (2025). Parkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation. [Retrieved from: https://www.researchgate.net/profile/Masaru-Tanaka-5/publication/393027271_Parkinson's_Disease_Bridging_Gaps_Building_Biomarkers_and_Reimagining_Clinical_Translation/links/685ce97699d2ce32c1cb439e/Parkinsons-Disease-Bridging-Gaps-Building-Biomarkers-and-Reimagining-Clinical-Translation.pdf] Retrieved on: 2.07.2025
• Tian, S. Y., Cao, X., Liu, G. J., Zi, Y., Zhu, H. X., Jiang, Y. M., ... & Zhuang, Q. X. (2025). Role of the Central Cholinergic Nervous System in Motor and Non-Motor Symptoms of Parkinson’s Disease. Current neuropharmacology. [Retrieved from:https://www.benthamdirect.com/content/journals/cn/10.2174/011570159X368923250313045859] Retrieved on: 2.07.2025